Haemonetics Corporation Provided Earnings Guidance for the fiscal year 2022. For the period, the company expects total company GAAP revenue guidance includes $65 Million to $75 million revenue related to the Cardiva Medical Vascular Closure devices. Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth in the mid-twenties. Organic total revenue expected to be in the range of 8% to 12%.